Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | PLK1 | P53350 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | SNCA | P37840 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CTRC | Q99895 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522946 | 1.00 | PDGFRB (0.54) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL12794839 | 0.90 | PDGFRB (0.54) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL6525491 | 0.85 | RET (0.57) | PLK4RETFLT3PIM1PSEN1 | |
| SCHEMBL6525485 | 0.85 | RET (0.57) | PLK4RETFLT3PIM1PSEN1 | |
| SCHEMBL6522510 | 0.85 | PLK4 (0.61) | PDGFRBPLK4PLK1RETKDR | |
| SCHEMBL6522514 | 0.85 | PLK4 (0.61) | PDGFRBPLK4PLK1RETKDR | |
| SCHEMBL6523868 | 0.84 | MGAM (0.52) | ERBB2EGFRPSEN1PSEN2APH1B | |
| SCHEMBL6523877 | 0.84 | MGAM (0.52) | ERBB2EGFRPSEN1PSEN2APH1B | |
| SCHEMBL6528268 | 0.80 | PDGFRB (0.54) | PDGFRBPLK4PLK1RETFLT3 | |
| SCHEMBL6528272 | 0.80 | PDGFRB (0.54) | PDGFRBPLK4PLK1RETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9402828-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2016-08-02 | — | — | US | disclosed |
| US-9402828-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2016-08-02 | — | — | US | disclosed |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2015-07-02 | — | — | US | disclosed |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8933070-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2015-01-13 | — | — | US | disclosed |
| US-8933070-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2015-01-13 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | PDGFRB 277/4885PLK4 23/4885PLK1 30/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | PDGFRB 692/4885PLK4 464/4885PLK1 4/4885 |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | PDGFRB 151/4885PLK4 139/4885PLK1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.